| |
Treatment
|
|---|
|
Time (Weeks)
|
Control
|
Bti
|
Spinosad
|
Temephos
|
|---|
|
Pre-treatment
| | | | |
|
-5
|
8.5 ± 3.9b
|
26.0 ± 12.7a
|
49.5 ± 26.6a
|
5.7 ± 2.9b
|
|
-4
|
19.8 ± 12.6b
|
44.0 ± 30.6ab
|
105.8 ± 56.2a
|
3.5 ± 1.3bc
|
|
-3
|
56.0 ± 22.8a
|
18.0 ± 7.0a
|
185.5 ± 129.8a
|
71.3 ± 61.9a
|
|
-2
|
65.0 ± 45.9b
|
74.3 ± 45.9ab
|
125.8 ± 73.1a
|
17.3 ± 6.0bc
|
|
-1
|
122.3 ± 43.7a
|
135.3 ± 84.3a
|
125.3 ± 67.6a
|
36.5 ± 7.6a
|
|
Post-treatment
| | | | |
|
1
|
132.3 ± 68.8a
|
2.8 ± 2.4b
|
0.0 ± 0.0b
|
0.0 ± 0.0b
|
|
2
|
21.0 ± 7.6a
|
15.5 ± 12.9a
|
0.0 ± 0.0b
|
0.0 ± 0.0b
|
|
3
|
143.0 ± 70.7a
|
51.5 ± 35.8b
|
0.0 ± 0.0c
|
0.0 ± 0.0c
|
|
4
|
90.5 ± 48.4a
|
45.5 ± 36.3a
|
0.0 ± 0.0b
|
0.0 ± 0.0b
|
|
5
|
49.8 ± 30.8a
|
13.0 ± 7.3a
|
0.0 ± 0.0b
|
0.0 ± 0.0b
|
|
6
|
184.8 ± 94.4a
|
30.5 ± 29.5b
|
0.0 ± 0.0c
|
0.8 ± 0.5bc
|
|
7
|
238.5 ± 133.2a
|
19.5 ± 14.2b
|
0.0 ± 0.0c
|
0.8 ± 0.8c
|
|
8
|
82.8 ± 35.8a
|
8.8 ± 6.9b
|
0.0 ± 0.0c
|
6.8 ± 4.5b
|
|
9
|
40.0 ± 19.5a
|
26.5 ± 18.5a
|
0.0 ± 0.0b
|
7.8 ± 5.7ab
|
|
10
|
55.0 ± 25.0a
|
28.8 ± 17.0a
|
0.0 ± 0.0b
|
19.3 ± 9.9a
|
|
11
|
39.0 ± 15.5a
|
23.5 ± 17.5ab
|
0.0 ± 0.0c
|
47.5 ± 16.8a
|
|
12
|
54.8 ± 17.3a
|
28.0 ± 17.2a
|
0.0 ± 0.0b
|
54.3 ± 20.7a
|
|
13
|
85.8 ± 43.7ab
|
46.0 ± 34.2b
|
0.0 ± 0.0c
|
184.8 ± 86.5a
|
|
14
|
44.8 ± 29.6b
|
136.3 ± 112.9b
|
0.0 ± 0.0c
|
327.8 ± 116.4a
|
|
15
|
42.3 ± 25.4b
|
125.3 ± 76.8a
|
0.0 ± 0.0c
|
228.8 ± 77.4a
|
|
20
|
13.0 ± 11.0ab
|
22.5 ± 15.7a
|
2.7 ± 2.7b
|
50.8 ± 26.6a
|
- Values followed by identical letters did not differ significantly for comparisons within rows (mixed model analysis on ln (x + 1) transformed values with Toeplitz correlation structure, P > 0.005 following Bonferroni correction).
